Reuters logo
BRIEF-European Commission approves Amgevita for treatment of certain inflammatory diseases
March 23, 2017 / 8:49 PM / 6 months ago

BRIEF-European Commission approves Amgevita for treatment of certain inflammatory diseases

March 23 (Reuters) - Amgen Inc

* European Commission approves Amgevita™ (biosimilar adalimumab) for the treatment of certain inflammatory diseases

* Amgen Inc- approval from EC grants a centralized marketing authorization with unified labeling in 28 countries that are members of EU Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below